0N6A.F TME PHARM.CONF.IPO EO 1-

Healthcare Biotechnology Frankfurt Exchange
0.1032 EUR
Close of Nov 11, 2026
0.0333 0.1798
Market cap
EUR 9.98M
P/E
-
P/B
5.94x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 0N6A.F undervalued?

Graham number

The Graham number of TME PHARM.CONF.IPO EO 1- cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

TME PHARM.CONF.IPO EO 1- fundamental analysis

No fundamental analysis for TME PHARM.CONF.IPO EO 1- yet.

TME PHARM.CONF.IPO EO 1- stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About TME PHARM.CONF.IPO EO 1-

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It al…

Full company profile